OCULAR THERAPEUTICS BY DESIGN Eleven Biotherapeutics designs and develops targeted therapeutics for ocular diseases based on its transformative protein engineering technology. We create a new breed of potent and selective ophthalmic proteins. Eleven is creating the next generation of engineered protein drugs for ocular diseases that are purposefully designed and tuned to have unique targeting capabilities and superior therapeutic properties, while maintaining the optimal natural attributes of the protein.
Our differentiated ophthalmic protein products are designed for superior therapeutic impact with unique capabilities previously unattainable in the ocular space. Eleven has a proprietary pipeline in ocular disease comprising protein products that are engineered to treat diseases in new and more effective ways.
Our technology unleashes innovative protein therapeutics. Eleven's proprietary protein engineering technology opens the potential to address key targets for which protein drugs are the best modulators for ocular diseases that are growing in prevalence.